跳至主要内容
临床试验/NCT01285089
NCT01285089已完成不适用

Prospective French Study on ACQUIred Haemophilia Treatment With Recombinant Factor VIIa (NovoSeven®) A Prospective Observational Study on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for the Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

Novo Nordisk A/S0 个研究点目标入组 21 人开始时间: 2010年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
21
主要终点
Identification of decision criteria to treat patient with activated recombinant human factor VII

研究概览

简要总结

This study is conducted in Europe. The aim of this prospective, observational study are to describe the different clinical practice and detailed haemostatic management of activated recombinant human factor VII (NovoSeven®) in patients with acquired haemophilia in France. The secondary aim is to assess the primary haemostasis disorder associated with the coagulation disorders, if available.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Diagnosed with acquired haemophilia
  • Treated with activated recombinant human factor VII as first line treatment
  • Treated with activated recombinant human factor VII after January 2011

排除标准

  • Patients with first diagnosis before january 2010 and having a relapse after january 2011
  • Known hypersensitivity to NovoSeven®, or to mouse, hamster or bovine protein

研究组 & 干预措施

A

干预措施: activated recombinant human factor VII (Drug)

结局指标

主要结局

Identification of decision criteria to treat patient with activated recombinant human factor VII

时间窗: Year 3

次要结局

  • Number of patients with a control of bleeding(Year 3)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验